Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Pro Medicus Limited ( (AU:PME) ) just unveiled an announcement.
Pro Medicus Limited has disclosed a small on-market share purchase by non-executive director Peter Terence Kempen, who increased his direct and associated holdings by 600 ordinary shares at a price of $224 per share. Following the transaction, Kempen’s total interest in the company rose to 629,682 shares held across his own name, the Elaine Kempen Superannuation Fund, and EMK Investments Pty Ltd, signalling continued insider confidence and marginally strengthening director alignment with shareholders.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
More about Pro Medicus Limited
Pro Medicus Limited is an Australian listed company operating in the healthcare technology sector, best known for its medical imaging IT solutions used by hospitals and diagnostic providers. The company focuses on advanced radiology and imaging software that supports clinical workflows and diagnostic decision-making across healthcare markets.
Average Trading Volume: 171,617
Technical Sentiment Signal: Hold
Current Market Cap: A$23.59B
See more data about PME stock on TipRanks’ Stock Analysis page.